Table 2.

Most frequently reported adverse events (safety population, n = 129)^*

	Number (%) of subjects
		Taspoglutide dose
Adverse event	Placebo once weekly n = 32	20 mg once weekly n = 32	20/30 mg once weekly n = 33	20/40 mg once weekly n = 32
Nausea	4 (13)	12 (38)	17 (52)	11 (34)
Headache	4 (13)	5 (16)	2 (6)	3 (9)
Diarrhoea	3 (9)	4 (13)	7 (21)	3 (9)
Fatigue	1 (3)	3 (9)	4 (12)	1 (3)
Vomiting	0	4 (13)	9 (27)	4 (13)
Dyspepsia	0	6 (19)	5 (15)	5 (16)
Abdominal distension	0	3 (9)	4 (12)	1 (3)

^*Adverse events that began during study treatment and occurred in ≥ 10% of subjects in any treatment group.